ChemicalBook > Product Catalog >Analytical Chemistry >Standard >Pharmaceutical Impurity Reference Standards >(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate

(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate

(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate Suppliers list
Company Name: Adamas Reagent, Ltd.  
Tel: 400-6009262 15618770481
Email: yhx@titansci.com
Company Name: Jinan Trio PharmaTech Co., Ltd.  
Tel: 0531-88811783
Email: sales@trio-pharmatech.com
Company Name: Daicel Chiral Technologies (China)CO.,LTD  
Tel: 021-50460086-9 15921403865
Email: han_yajun@dctc.daicel.com
Company Name: Bide Pharmatech Ltd.  
Tel: 400-164-7117 18317119277
Email: product02@bidepharm.com
Company Name: Quality Control Solutions Ltd.  
Tel: 0755-66853366 13670046396
Email: orders@qcsrm.com
(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate Basic information
Product Name:(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate
Synonyms:(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate;(4R)-5-[1,1'-Biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-2-pentenoic acid ethyl ester;2-Pentenoic acid, 5-[1,1'-biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-, ethyl ester, (4R)-;Ethyl 5-(4-[1,1'-biphenyl]yl)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-2-pentenoate;LCZ696 59-1;(R)-Ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoate;LCZ-696-003-R;LCZ696(valsartan + sacubitril) impurity 24
CAS:149709-59-1
MF:C25H31NO4
MW:409.52
EINECS:
Product Categories:LCZ696
Mol File:149709-59-1.mol
(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate Structure
(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate Chemical Properties
Boiling point 562.7±50.0 °C(Predicted)
density 1.081±0.06 g/cm3(Predicted)
storage temp. 2-8°C
pka11.14±0.46(Predicted)
AppearanceOff-white to light yellow Solid
Optical Rotation-31.5534°(C=0.5665g/100ml CHCL3)
Safety Information
MSDS Information
(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate Usage And Synthesis
Uses(R)-Ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoate is used to prepare dicarboxylic acid dipeptide neutral endopeptidase inhibitors.
Synthesis
METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE

149818-98-4

2-(triphenyl-phosphanylidene)-propionic acid ethyl ester

21382-82-1

(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate

149709-59-1

Step 5: 23.3 g of the product of Step 4 ((R,E)-ethyl 5-([1,1'-biphenylyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoate, 65.6 mmol, 1.0 eq.) was dissolved in 300 mL of dichloromethane (DCM) and cooled under a nitrogen (N2) atmosphere to -70° C. At this temperature, dropwise 109 mL of diisobutylaluminum hydride (DIBAL-H, 1.5 M toluene solution, 164 mmol, 2.5 eq.) was added. After stirring for 15 minutes, thin layer chromatography (TLC) analysis showed that there was still raw material residue. Subsequently, an additional 15 mL of DIBAL-H (1.5 M toluene solution) was added dropwise and stirring was continued for 5 minutes at -70°C. TLC showed that the reaction was complete. The reaction solution was slowly poured into 450 mL of 1 M aqueous hydrochloric acid (HCl), keeping the temperature below 0°C. After stirring for a few minutes, the organic layer was separated and the aqueous phase was extracted with DCM (100 mL × 2). The combined organic layers were washed sequentially with aqueous sodium bicarbonate (NaHCO3) (150 mL) and water (100 mL) and dried over anhydrous sodium sulfate (Na2SO4). After filtration, 19.0 g of ethyl 2-(triphenylphosphoranylidene)propionate was added to the solution, keeping the temperature below 5°C. The resulting solution was stirred at 25°C for 18 h. TLC showed that the reaction was complete. The reaction solution was concentrated, purified by silica gel column chromatography (petroleum ether/ethyl acetate = 4/1) and then crystallized from petroleum ether/ethyl acetate (80 mL/20 mL) to afford 17.0 g of ethyl (4R)-5-[1,1'-biphenyl]-4-yl-4-[[tert-butoxycarbonyl]amino]-2-methyl-2-pentenoate (chemical purity > 99.5%) as a white solid. Total yield in two steps: 89.1%.

References[1] Patent: WO2015/154673, 2015, A1. Location in patent: Page/Page column 16
Tag:(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate(149709-59-1) Related Product Information
N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine benzyl ester (2R,4S)-4-([1,1'-Biphenyl]-4-ylmethyl)-4-(4-ethoxy-4-oxobutanamido)-2-methylbutanoic acid Ethyl (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoate (2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid Valsartan AHU-377 (heMicalciuM salt) (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid sacubitril (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoate LCZ696 InteMediate (S)-5-[(Biphenyl-4-yl)carbonyl]pyrrolidin-2-one AHU-377 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride LCZ Impurity (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid (2S,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid